Merck Shares Slump 0.69 as 1.3B Trading Volume Plunges 56 to 75th in Liquidity Ranking

On October 2, 2025, Merck (MRK) closed with a 0.69% decline, trading at a volume of $1.30 billion, a 56.33% drop from the previous day’s activity, ranking it 75th in terms of liquidity among listed stocks. The pharmaceutical giant’s shares faced downward pressure amid evolving market dynamics and sector-specific challenges.

Recent developments highlighted Merck’s strategic focus on its oncology pipeline, with updated trial data for its key immuno-oncology candidate reinforcing long-term growth expectations. However, short-term volatility emerged as investors recalibrated positions following mixed guidance from industry peers. Analysts noted that while the company’s R&D progress remains robust, near-term earnings visibility remains constrained by regulatory timelines and competitive landscape shifts.

To ensure precise back-testing execution, clarification is required on several parameters. The universe scope must confirm whether to include all U.S.-listed stocks or limit to S&P 500 constituents. Rebalancing frequency, price execution rules, and handling of incomplete data—such as halted stocks—will directly impact the accuracy of the resulting statistics and visualizations. Finalizing these details is critical to align the test with intended objectives.